{
  "metadata": {
    "source_file": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/01_Article_Iptacopan C3G Trial.pdf",
    "extracted_at": "2026-02-04T14:34:36.037960"
  },
  "count": 3,
  "tables": [
    {
      "visual_id": "a5820fc6-84e8-4548-9318-deb2580d737a",
      "visual_type": "table",
      "confidence": 1.0,
      "page_range": [
        4
      ],
      "is_multipage": false,
      "locations": [
        {
          "page_num": 4,
          "bbox_pts": [
            118.47684478759766,
            127.55110931396484,
            332.6581726074219,
            547.020263671875
          ]
        }
      ],
      "title": "Baseline Patient Characteristics for Clinical Trial",
      "description": "This is a data table comparing baseline demographic and clinical characteristics between two treatment groups in a clinical trial: Iptacopan 200 mg (n=38) versus Placebo (n=36). The table presents comprehensive patient information including age, sex, race, geographic region, ethnicity, baseline urinary protein levels, and kidney function measures (eGFR). Notable patterns include a higher proportion of males in the Iptacopan group (71% vs 56%), higher baseline proteinuria in the Iptacopan group (geometric mean UPCR 3.33 vs 2.58 g/g), and lower baseline kidney function in the Iptacopan group (mean eGFR 89.3 vs 99.2 mL/min per 1.73 m²).",
      "caption": "Table 1: Baseline characteristics",
      "reference": "Table 1",
      "image_file": "01_Article_Iptacopan C3G Trial_table_page4_1.png",
      "table_data": {
        "structure": {
          "headers": [
            [
              "",
              "Iptacopan200mg (n=38)",
              "Placebo (n=36)"
            ]
          ],
          "rows": [
            [
              "Age (years), mean (SD)",
              "26·1 (10·39)",
              "29·8 (10·79)"
            ],
            [
              "Sex",
              "",
              ""
            ],
            [
              "Male",
              "27 (71%)",
              "20 (56%)"
            ],
            [
              "Female",
              "11 (29%)",
              "16 (44%)"
            ],
            [
              "Race",
              "",
              ""
            ],
            [
              "White",
              "27 (71%)",
              "24 (67%)"
            ],
            [
              "Black or African American",
              "1 (3%)",
              "1 (3%)"
            ],
            [
              "Asian",
              "9 (24%)",
              "9 (25%)"
            ],
            [
              "American Indian or",
              "0",
              "1 (3%)"
            ],
            [
              "Multiple",
              "0",
              "1 (3%)"
            ],
            [
              "Unknown",
              "1 (3%)",
              "0"
            ],
            [
              "Region",
              "",
              ""
            ],
            [
              "North America",
              "7 (18%)",
              "8 (22%)"
            ],
            [
              "Europe",
              "22 (58%)",
              "19 (53%)"
            ],
            [
              "Other",
              "9 (24%)",
              "9 (25%)"
            ],
            [
              "Ethnicity",
              "",
              ""
            ],
            [
              "Hispanic or Latino",
              "1 (3%)",
              "6 (17%)"
            ],
            [
              "Not Hispanic or Latino",
              "34 (89%)",
              "29 (81%)"
            ],
            [
              "Not reported",
              "2 (5%)",
              "0"
            ],
            [
              "Unknown",
              "1 (3%)",
              "1 (3%)"
            ],
            [
              "Baseline 24-hUPCR (g/g), geometric mean (95%CI)",
              "3·33 (2·79-3·97)",
              "2·58 (2·18-3·05)"
            ],
            [
              "Baseline 24-hUPCR (3 g/g)",
              "",
              ""
            ],
            [
              "<339 g/mol",
              "17 (45%)",
              "25 (69%)"
            ],
            [
              "≥339 g/mol",
              "21 (55%)",
              "11 (31%)"
            ],
            [
              "Baseline 24-h total urinary protein (3",
              "g/day)",
              ""
            ],
            [
              "<3000 mg/day",
              "11 (29%)",
              "15 (42%)"
            ],
            [
              "≥3000 mg/day",
              "27 (71%)",
              "21 (58%)"
            ],
            [
              "Baseline eGFR (mL/min per 1·73 m2), mean (SD)",
              "89·3 (35·20)",
              "99·2 (26·88)"
            ],
            [
              "Baseline eGFR",
              "",
              ""
            ],
            [
              "<60 mL/min per 1·73 m2",
              "10 (26%)",
              "4 (11%)"
            ],
            [
              "≥60 mL/min per 1·73 m2",
              "28 (74%)",
              "32 (89%)"
            ],
            [
              "",
              "(Table 1 continues in next",
              "column)"
            ]
          ],
          "confidence": 0.85
        }
      },
      "relationships": {
        "text_mentions": [
          {
            "text": "\n(Table 1",
            "page_num": 4,
            "char_offset": 2842
          },
          {
            "text": " \nTable 1",
            "page_num": 4,
            "char_offset": 4540
          },
          {
            "text": "in table 1",
            "page_num": 6,
            "char_offset": 3258
          },
          {
            "text": " (table 1)",
            "page_num": 6,
            "char_offset": 3577
          },
          {
            "text": " (table 1",
            "page_num": 6,
            "char_offset": 3649
          }
        ],
        "section_context": "Methods",
        "continued_from": null,
        "continues_to": null
      },
      "provenance": {
        "extraction_method": "docling+vlm",
        "source_file": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/01_Article_Iptacopan C3G Trial.pdf",
        "extracted_at": "2026-02-04T13:35:50.372887"
      },
      "triage": {
        "decision": "vlm",
        "reason": "docling_table"
      }
    },
    {
      "visual_id": "1d7328d6-f661-452b-b5fa-dd636cd76df1",
      "visual_type": "table",
      "confidence": 1.0,
      "page_range": [
        4
      ],
      "is_multipage": false,
      "locations": [
        {
          "page_num": 4,
          "bbox_pts": [
            344.41229248046875,
            127.93586730957031,
            558.8248901367188,
            527.0745849609375
          ]
        }
      ],
      "title": "Baseline Patient Characteristics by Treatment Group",
      "description": "This is a data table comparing baseline demographic and clinical characteristics between patients receiving Iptacopan 200 mg (n=38) versus placebo (n=36) in what appears to be a clinical trial for C3 glomerulopathy. The table presents detailed patient information including kidney function measures (eGFR, blood pressure), C3 complement levels, disease duration and subtype, and concurrent treatments. Notable findings include similar baseline characteristics between groups, with C3 glomerulonephritis being the most common subtype (68% in Iptacopan group vs 89% in placebo group) and about half of patients in each group having reduced kidney function (eGFR <90 mL/min).",
      "caption": "Table 1: Baseline characteristics",
      "reference": "Table 1",
      "image_file": "01_Article_Iptacopan C3G Trial_table_page4_2.png",
      "table_data": {
        "structure": {
          "headers": [
            [
              "",
              "Iptacopan200mg (n=38)",
              "Placebo (n=36)"
            ]
          ],
          "rows": [
            [
              "(Continued from previous column)",
              "(Continued from previous column)",
              "(Continued from previous column)"
            ],
            [
              "Baseline eGFR",
              "",
              ""
            ],
            [
              "<90 mL/min per 1·73 m2",
              "19 (50%)",
              "12 (33%)"
            ],
            [
              "≥90 mL/min per 1·73 m2",
              "19 (50%)",
              "24 (67%)"
            ],
            [
              "Has hypertension",
              "23 (61%)",
              "18 (50%)"
            ],
            [
              "Sitting systolic blood pressure (mmHg), mean (SD)",
              "125·8 (13·30)",
              "122·6 (11·43)"
            ],
            [
              "Sitting diastolic blood pressure (mmHg), mean (SD)",
              "77·7 (8·77)",
              "77·7 (8·47)"
            ],
            [
              "BaselineC3 (mg/L), mean (SD)",
              "316·8 (243·41)",
              "339·3 (227·96)"
            ],
            [
              "Age atC3 glomerulopathy diagnosis (years), mean (SD)",
              "22·0 (10·88)",
              "25·3 (10·80)"
            ],
            [
              "Years sinceC3 glomerulopathy diagnosis",
              "Years sinceC3 glomerulopathy diagnosis",
              "Years sinceC3 glomerulopathy diagnosis"
            ],
            [
              "<2years",
              "15 (39%)",
              "15 (42%)"
            ],
            [
              "≥2years",
              "23 (61%)",
              "21 (58%)"
            ],
            [
              "C3 glomerulopathy subtype at diagnosis",
              "C3 glomerulopathy subtype at diagnosis",
              "C3 glomerulopathy subtype at diagnosis"
            ],
            [
              "C3 glomerulonephritis",
              "26 (68%)",
              "32 (89%)"
            ],
            [
              "Dense deposit disease",
              "9 (24%)",
              "1 (3%)"
            ],
            [
              "MixedC3 glomerulonephritis and dense deposit disease",
              "2 (5%)",
              "2 (6%)"
            ],
            [
              "Unknown",
              "1 (3%)",
              "1 (3%)"
            ],
            [
              "Corticosteroid treatment, mycophenolic acid treatment, or both, at time of random",
              "16 (42%)",
              "17 (47%)"
            ],
            [
              "allocation Data are n(%)unless otherwise indicated. Baseline 24-hUPCRreferstoUPCR as measured bythe geometric meanoftwo24-hurine collections at baseline. Baseline 24-htotal urinary protein refers to total urinary protein as measured bythe geometric meanoftwo24-hurine collections at baseline. Baseline eGFRwasdefined asthe arithmetic meanoftwoeGFRvalues atthe day -15 visit (before",
              "allocation Data are n(%)unless otherwise indicated. Baseline 24-hUPCRreferstoUPCR as measured bythe geometric meanoftwo24-hurine collections at baseline. Baseline 24-htotal urinary protein refers to total urinary protein as measured bythe geometric meanoftwo24-hurine collections at baseline. Baseline eGFRwasdefined asthe arithmetic meanoftwoeGFRvalues atthe day -15 visit (before",
              "allocation Data are n(%)unless otherwise indicated. Baseline 24-hUPCRreferstoUPCR as measured bythe geometric meanoftwo24-hurine collections at baseline. Baseline 24-htotal urinary protein refers to total urinary protein as measured bythe geometric meanoftwo24-hurine collections at baseline. Baseline eGFRwasdefined asthe arithmetic meanoftwoeGFRvalues atthe day -15 visit (before"
            ]
          ],
          "confidence": 0.85
        }
      },
      "relationships": {
        "text_mentions": [
          {
            "text": "\n(Table 1",
            "page_num": 4,
            "char_offset": 2842
          },
          {
            "text": " \nTable 1",
            "page_num": 4,
            "char_offset": 4540
          },
          {
            "text": "in table 1",
            "page_num": 6,
            "char_offset": 3258
          },
          {
            "text": " (table 1)",
            "page_num": 6,
            "char_offset": 3577
          },
          {
            "text": " (table 1",
            "page_num": 6,
            "char_offset": 3649
          }
        ],
        "section_context": "Methods",
        "continued_from": null,
        "continues_to": null
      },
      "provenance": {
        "extraction_method": "docling+vlm",
        "source_file": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/01_Article_Iptacopan C3G Trial.pdf",
        "extracted_at": "2026-02-04T13:35:50.372935"
      },
      "triage": {
        "decision": "vlm",
        "reason": "docling_table"
      }
    },
    {
      "visual_id": "8c4555c3-ecbd-4a16-afee-ebb8db3eedfc",
      "visual_type": "table",
      "confidence": 1.0,
      "page_range": [
        9
      ],
      "is_multipage": false,
      "locations": [
        {
          "page_num": 9,
          "bbox_pts": [
            39.09846496582031,
            129.26727294921875,
            249.85354614257812,
            345.47772216796875
          ]
        }
      ],
      "title": "Iptacopan vs Placebo Adverse Events Comparison",
      "description": "This is a clinical trial safety data table comparing adverse events between Iptacopan 200mg (n=38) and placebo (n=36) groups during a 6-month double-blind treatment period. The table shows that both groups had similar overall rates of treatment-emergent adverse events (70% vs 67%), with most events being mild in severity. Notable differences include more moderate adverse events in the Iptacopan group (24% vs 6%) and slightly more serious adverse events (8% vs 3%), though no deaths or drug discontinuations occurred in either group.",
      "caption": "Adverse events during the 6-month double-blind treatment period",
      "reference": "Table 2",
      "image_file": "01_Article_Iptacopan C3G Trial_table_page9_1.png",
      "table_data": {
        "structure": {
          "headers": [
            [
              "",
              "Iptacopan200mg (n=38)",
              "Placebo (n=36)"
            ]
          ],
          "rows": [
            [
              "Numberof participants with at",
              "30 (79%)",
              "24 (67%)"
            ],
            [
              "least one treatment-emergent adverse event",
              "",
              ""
            ],
            [
              "Mild",
              "19 (50%)",
              "21 (58%)"
            ],
            [
              "Moderate",
              "9 (24%)",
              "2 (6%)"
            ],
            [
              "Severe",
              "2 (5%)",
              "1 (3%)"
            ],
            [
              "Suspected to be related to study medication",
              "7 (18%)",
              "4 (11%)"
            ],
            [
              "Serious adverse events",
              "3 (8%)",
              "1 (3%)"
            ],
            [
              "Blood culture positive for",
              "1 (3%)",
              "0"
            ],
            [
              "Streptococcus pneumoniae Infected bite",
              "1 (3%)",
              "0"
            ],
            [
              "Chest discomfort",
              "1 (3%)",
              "0"
            ],
            [
              "Acute kidney injury",
              "0",
              "1 (3%)"
            ],
            [
              "Ascites",
              "0",
              "1 (3%)"
            ],
            [
              "Adverse events leading to study drug discontinuation",
              "0",
              "0"
            ],
            [
              "Deaths",
              "0",
              "0"
            ]
          ],
          "confidence": 0.85
        }
      },
      "relationships": {
        "text_mentions": [
          {
            "text": " (table 2)",
            "page_num": 9,
            "char_offset": 1175
          },
          {
            "text": " (table 2)",
            "page_num": 9,
            "char_offset": 1942
          },
          {
            "text": "\nTable 2",
            "page_num": 9,
            "char_offset": 5324
          }
        ],
        "section_context": "Results",
        "continued_from": null,
        "continues_to": null
      },
      "provenance": {
        "extraction_method": "docling+vlm",
        "source_file": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/01_Article_Iptacopan C3G Trial.pdf",
        "extracted_at": "2026-02-04T13:35:50.372968"
      },
      "triage": {
        "decision": "vlm",
        "reason": "has_caption"
      }
    }
  ]
}